Thirteen Studies of Ascentage Pharma's Assets Including Olverembatinib and Lisaftoclax Selected for Presentations at 2025 European Hematology Association Annual Congress
The EHA Annual Congress is the largest gathering of the hematology community in Europe. Attracting more than 10,000 attendees from more than 100 countries every year, the congress showcases cutting-edge research and ground-breaking clinical results in the field of hematology.
Oral PresentationIntegrating Genomic and Transcriptomic Insights for Predicting Responses and Outcomes in Patients with CML Receiving 3rd-Generation TKI Therapy
Abstract#: S162
Session: Biology of CML treatment response and resistance
Date and Time: Saturday, 14 June, 17:30-17:45 CEST / Saturday, 14 June, 23:30-23:45 Beijing Time
Principal Authors: Prof. Qian Jiang, Peking University People's Hospital; Dr. Xiaoshuai Zhang, Peking University People's Hospital
Poster PresentationsFrontline Chemotherapy-Free Combination of Olverembatinib with Venetoclax and Azacitidine in Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia: Preliminary Outcomes of a Prospective Study
Abstract#: PF384
Session: Acute lymphoblastic leukemia – Clinical
Date and Time: Friday, 13 June, 18:30-19:30 CEST / Saturday, 14 June, 00:30-01:30 Beijing Time
Principal Author: Prof. Xiaowen Tang, The First Affiliated Hospital of Soochow University; Xin Zhang, The First Affiliated Hospital of Soochow University
A Phase 2 Study of Olverembatinib for the Treatment of Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
Abstract#: PF390
Session: Acute lymphoblastic leukemia – Clinical
Date and Time: Friday, 13 June, 18:30-19:30 CEST / Saturday, 14 June, 00:30-01:30 Beijing Time
Principal Authors: Prof. Suning Chen, The First Affiliated Hospital of Soochow University; Wenzhi Cai, The First Affiliated Hospital of Soochow University
Efficacy and Safety of Regimen with Olverembatinib and Blinatumomab for the Frontline Treatment of Ph-Positive or Ph-Like Acute Lymphoblastic Leukemia
Abstract#: PS1367
Session: Acute lymphoblastic leukemia – Clinical
Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Beijing Time
Principal Authors: Prof. Hongsheng Zhou, Nanfang Hospital, Southern Medical University; Xiuli Xu, Nanfang Hospital, Southern Medical University
Combination of Olverembatinib and VP Regimen as First-Line Therapy for Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Single-Arm, Multicentre, Phase 2 Trial
Abstract#: PS1372
Session: Acute lymphoblastic leukemia – Clinical
Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Beijing Time
Principal Authors: Prof. Jie Jin, The First Affiliated Hospital, Zhejiang University School of Medicine; Dr. Gaixiang Xu, The First Affiliated Hospital, Zhejiang University School of Medicine
Efficacy and Safety of The Third-Generation Tyrosine Kinase Inhibitor Olverembatinib in Combination with Inotuzumab Ozogamicin for the Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients With Relapsed Disease or Persistent Minimal Residual Disease Bridging to Hematopoietic Stem Cell Transplantation: A Phase II Study
Abstract#: PS1387
Session: Acute lymphoblastic leukemia – Clinical
Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30 Beijing Time
Principal Author: Erlie Jiang, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Xiaoyu Zhang, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Embryonic Ectoderm Development (EED) Inhibitor APG-5918 Exhibits Potent Antitumor Activity and Synergizes with Histone Deacetylase Inhibitor Tucidinostat in PreclinicalT-Cell Lymphoma (TCL) Models
Abstract#: PS1993
Session: Lymphoma biology & translational research
Date and Time: Saturday, 14 June, 18:30-19:30 CEST / Sunday, 15 June, 00:30-01:30
Principal Author: Dr. Eric Liang, Ascentage Pharma Group Inc.
Online PublicationsAlternating Low-Dose Inotuzumab Ozogamicin and Blinatumomab in Maintenance Therapy for Ph+ ALL: A Single-Center Retrospective Analysis
Abstract: PB2384
Principal Author: Prof. Zi-Yuan Nie, The Second Hospital of Hebei Medical University
Efficacy and Safety of Blinatumomab in Newly-Diagnosed Patients with Ph-Positive/Negative B-Cell Acute Lymphoblastic Leukemia
Abstract#: PB2363
Principal Author: Yinqiang Zhang, Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Efficacy and Safety of the Third-Generation TKI Olverembatinib in Relapsed and Persistent MRD Positive Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients
Abstract#: PB2360
Principal Author: Xinwen Jiang, The Second Hospital of Hebei Medical University
Clinical Features and Genetic Abnormalities Predict Outcomes in Patients with Chronic Myeloid Leukemia in the Accelerated-Phase Receiving Olverembatinib Therapy: A Retrospective Multicenter Study
Abstract#: PB2701
Principal Author: Mengyao Yuan, Peking University People's Hospital
A Real-World Study of Olverembatinib in the Treatment of Chronic Myeloid Leukemia from China: A Single-Center Retrospective Study
Abstract#: PB2714
Principal Author: Tian Dong, West China Hospital of Sichuan University
Synergistic Effects of Olverembatinib (HQP1351) Combined with Bcl-2 Inhibitor Lisaftoclax (APG-2575) and Bcl-2/Bcl-xL Inhibitor Pelcitoclax (APG-1252) in T-Cell Acute Lymphoblastic Leukemia (T-ALL)
Abstract#: PB2341
Principal Author: Bo Peng, Ascentage Pharma (Suzhou) Co., Ltd.
About Ascentage PharmaAscentage Pharma (NASDAQ: AAPG; HKEX: 6855) is a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers. The company has built a rich pipeline of innovative drug candidates that includes inhibitors targeting key proteins in the apoptotic pathway, such as Bcl-2 and MDM2-p53 and next-generation kinase inhibitors.
The lead asset, olverembatinib, is the first novel third-generation BCR-ABL1 inhibitor approved in China for the treatment of patients with CML in chronic phase (CML-CP) with T315I mutations, CML in accelerated phase (CML-AP) with T315I mutations, and CML-CP that is resistant or intolerant to first and second-generation TKIs. It is covered by the China National Reimbursement Drug List (NRDL). The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or POLARIS-2, of olverembatinib for CML, as well as global registrational Phase III trials for newly diagnosed Ph+ ALL patients and SDH-deficient GIST patients.
The second lead asset, lisaftoclax, is a novel Bcl-2 inhibitor for the treatment of various hematologic malignancies. The NDA for the treatment of relapsed and/or refractory CLL and SLL was accepted with Priority Review designation by China's National Medical Products Administration. The Company is currently conducting an FDA-cleared, global registrational Phase III trial, or GLORA, of lisaftoclax in combination with BTK inhibitors for patients with CLL/SLL previously treated with BTK inhibitors for more than 12 months with suboptimal response, as well as global registrational Phase III trials for newly diagnosed CLL/SLL, AML, and MDS patients.
Leveraging its robust R&D capabilities, Ascentage Pharma has built a portfolio of global intellectual property rights and entered into global partnerships and other relationships with numerous leading biotechnology and pharmaceutical companies, such as Takeda, AstraZeneca, Merck, Pfizer, and Innovent, in addition to research and development relationships with leading research institutions, such as Dana-Farber Cancer Institute, Mayo Clinic, National Cancer Institute and the University of Michigan. For more information, visit https://ascentage.com/
Forward-Looking StatementsThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, contained in this press release may be forward-looking statements, including statements that express Ascentage Pharma's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results of operations or financial condition. These forward-looking statements are subject to a number of risks and uncertainties as discussed in Ascentage Pharma's filings with the SEC, including those set forth in the sections titled 'Risk factors' and 'Special note regarding forward-looking statements and industry data' in its Registration Statement on Form F-1, as amended, filed with the SEC on January 21, 2025, and the Form 20-F filed with the SEC on April 16, 2025, the sections headed 'Forward-looking Statements' and 'Risk Factors' in the prospectus of the Company for its Hong Kong initial public offering dated October 16, 2019, and other filings with the SEC and/or The Stock Exchange of Hong Kong Limited we made or make from time to time that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. The forward-looking statements contained in this presentation do not constitute profit forecast by the Company's management.
As a result of these factors, you should not rely on these forward-looking statements as predictions of future events. The forward-looking statements contained in this press release are based on Ascentage Pharma's current expectations and beliefs concerning future developments and their potential effects and speak only as of the date of such statements. Ascentage Pharma does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investor Relations:
Hogan Wan, Head of IR and Strategy
Ascentage Pharma
Hogan.Wan@ascentage.com
+86 512 85557777
Stephanie Carrington
ICR Healthcare
Stephanie.Carrington@icrhealthcare.com
+1 (646) 277-1282
Media Relations:
Sean Leous
ICR Healthcare
Sean.Leous@icrhealthcare.com
+1 (646) 866-4012
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Tesla, Inc. (TSLA): Some People Are 'Gleeful' About Bad Car Sales, Reveals Jim Cramer
We recently published . Tesla, Inc. (NASDAQ:TSLA) is one of the stocks Jim Cramer recently discussed. Cramer discusses Tesla, Inc. (NASDAQ:TSLA) in nearly every morning appearance. This is partly due to the firm's CEO Elon Musk, whose recent back-and-forth with President Trump has caught media attention. After their first bout last month, Cramer wondered whether Tesla, Inc. (NASDAQ:TSLA) could maintain stable stock performance if Trump was displeased with Musk. Cramer also agrees with Musk on the fact that the firm's narrative will be determined by self-driving and humanoid robots instead of vehicle deliveries. In this show, he commented on Tesla, Inc. (NASDAQ:TSLA)'s share performance after Trump and Musk disagreed on the former's legislative efforts: '. . .this is the first time that I've seen this stock get crushed because the President did say that the subsidies, he's [Musk] the most subsidized person in America, alluded to maybe a trip to South Africa. . . Cramer continued to discuss Musk and Trump later in the day on Mad Money: 'Tesla, total dice roll. We have no idea what Elon Musk and the man in the White House, who may be the best name caller,… are going to do. But they sure don't seem like they're on great terms. So my plan is to have the president give Elon the right to have driverless cars on the interstate. I'm calling that plan shelved. But moral? There are usual ways to make a lot of money, but it's really fun to talk about Elon.' While we acknowledge the potential of TSLA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
2 Profitable Stocks with Exciting Potential and 1 to Turn Down
Even if a company is profitable, it doesn't always mean it's a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. Profits are valuable, but they're not everything. At StockStory, we help you identify the companies that have real staying power. That said, here are two profitable companies that generate reliable profits without sacrificing growth and one that may struggle to keep up. Trailing 12-Month GAAP Operating Margin: 3.3% A public company since early 2020, OneWater Marine (NASDAQ:ONEW) sells boats, yachts, and other marine products. Why Are We Hesitant About ONEW? Poor same-store sales performance over the past two years indicates it's having trouble bringing new shoppers into its brick-and-mortar locations Falling earnings per share over the last four years has some investors worried as stock prices ultimately follow EPS over the long term 7× net-debt-to-EBITDA ratio shows it's overleveraged and increases the probability of shareholder dilution if things turn unexpectedly OneWater is trading at $14.66 per share, or 8.1x forward P/E. If you're considering ONEW for your portfolio, see our FREE research report to learn more. Trailing 12-Month GAAP Operating Margin: 22% Founded in 1957, HEICO (NYSE:HEI) manufactures and services aerospace and electronic components for commercial aviation, defense, space, and other industries. Why Will HEI Outperform? Average organic revenue growth of 9.6% over the past two years demonstrates its ability to expand independently without relying on acquisitions Earnings growth has trumped its peers over the last two years as its EPS has compounded at 25.2% annually HEI is a free cash flow machine with the flexibility to invest in growth initiatives or return capital to shareholders At $324.67 per share, HEICO trades at 69.8x forward P/E. Is now a good time to buy? Find out in our full research report, it's free. Trailing 12-Month GAAP Operating Margin: 9.7% With around a century of experience, Blue Bird (NASDAQ:BLBD) is a manufacturer of school buses and complementary parts. Why Do We Love BLBD? Market share has increased this cycle as its 16.5% annual revenue growth over the last two years was exceptional Additional sales over the last two years increased its profitability as the 156% annual growth in its earnings per share outpaced its revenue Returns on capital are climbing as management makes more lucrative bets Blue Bird's stock price of $45.50 implies a valuation ratio of 10.7x forward P/E. Is now the time to initiate a position? See for yourself in our comprehensive research report, it's free. The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025. While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today Sign in to access your portfolio
Yahoo
8 hours ago
- Yahoo
This $11.5M Startup Backed By Niklas Zennström Wants To Help You Launch A Million-Dollar AI Business From Your Sofa
Henrik Werdelin, co-founder of BarkBox and longtime startup advisor, has launched a new venture named Audos, which recently raised $11.5 million in seed funding led by True Ventures. Other investors include Offline Ventures, Bungalow Capital, and notable angel investors Niklas Zennström and Mario Schlosser, TechCrunch reports. Based in New York, Audos offers AI tools and startup-building support to everyday people who want to launch small businesses without any technical background. Unlike accelerators or traditional venture models, TechCrunch says that Audos charges a 15% perpetual revenue share instead of taking equity from founders. Don't Miss: Invest early in CancerVax's breakthrough tech aiming to disrupt a $231B market. Tired of Grid Failures and Charging Deserts? This Startup Has a Solar Fix and $25M+ in Sales — Werdelin, who previously built startup studio Prehype, told TechCrunch that Audos combines years of startup-building expertise into an accessible platform anyone can use to launch a digital product. "What we're trying to do is to figure out how you make a million companies that do a million dollars [in annual revenue]," Werdelin said. That goal, if realized, would create what he calls a trillion-dollar turnover business, a term that sets a new benchmark for bottom-up innovation. The company uses social media platforms like Instagram and Facebook to reach potential founders and identify whether their business ideas can generate customers at a sustainable cost. According to TechCrunch, Audos's AI agent interacts with users directly, helping them clarify their offer and go to market quickly using natural language inputs. Trending: Named a TIME Best Invention and Backed by 5,000+ Users, Kara's Air-to-Water Pod Cuts Plastic and Costs — So far, Audos has supported the launch of what Werdelin calls "low hundreds" of businesses in its beta phase, TechCrunch reports. These include ventures like a virtual golf swing coach, an AI nutritionist, a mechanic offering quote evaluations, and even an "after-death logistics" consultant. Each founder received up to $25,000 in funding, access to Audos's proprietary tools, and support in distributing their offer through paid social ads. According to TechCrunch, Werdelin refers to these micro-businesses as "donkeycorns," signaling modest yet profitable ventures that aim to support personal freedom rather than billion-dollar exits. According to TechCrunch, Audos's model may spark discussion over the long-term cost of a 15% revenue share, which continues indefinitely like Apple's (NASDAQ:AAPL) App Store platform fee. While some entrepreneurs may welcome the no-equity route, others could see the permanent cut as a costly tradeoff over acknowledged that the market is rapidly filling with similar AI tools, saying, "the world is full of these tools" and they are "getting better rapidly," TechCrunch says. Audos distinguishes itself by helping non-technical users go to market quickly using natural language prompts and social media targeting. True Ventures partner Tony Conrad expressed confidence in Audos, citing its potential to support thousands who want to start small, independent businesses with real revenue potential. "There are just lots and lots of people" who need this opportunity, Conrad told TechCrunch. Audos currently operates with just five employees but aims to expand its impact exponentially without building a large internal team. Werdelin believes the next wave of entrepreneurship should be built by people previously left out of the ecosystem. "We believe that the world is better with more entrepreneurship," he told TechCrunch, pointing to mom-and-pop shops as his inspiration rather than venture-backed unicorns. Read Next: Here's what Americans think you need to be considered wealthy. Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article This $11.5M Startup Backed By Niklas Zennström Wants To Help You Launch A Million-Dollar AI Business From Your Sofa originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
